WO2005048944A3 - Activatable photodynamic therapy agents - Google Patents

Activatable photodynamic therapy agents Download PDF

Info

Publication number
WO2005048944A3
WO2005048944A3 PCT/US2004/038024 US2004038024W WO2005048944A3 WO 2005048944 A3 WO2005048944 A3 WO 2005048944A3 US 2004038024 W US2004038024 W US 2004038024W WO 2005048944 A3 WO2005048944 A3 WO 2005048944A3
Authority
WO
WIPO (PCT)
Prior art keywords
photodynamic therapy
therapy agents
activatable
methods
present
Prior art date
Application number
PCT/US2004/038024
Other languages
French (fr)
Other versions
WO2005048944A2 (en
Inventor
Gang Zheng
Jerry D Glickson
Britton Chance
Edward James Delikatny
Original Assignee
Univ Pennsylvania
Gang Zheng
Jerry D Glickson
Britton Chance
Edward James Delikatny
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pennsylvania, Gang Zheng, Jerry D Glickson, Britton Chance, Edward James Delikatny filed Critical Univ Pennsylvania
Publication of WO2005048944A2 publication Critical patent/WO2005048944A2/en
Publication of WO2005048944A3 publication Critical patent/WO2005048944A3/en
Priority to US11/383,487 priority Critical patent/US8133482B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0076—PDT with expanded (metallo)porphyrins, i.e. having more than 20 ring atoms, e.g. texaphyrins, sapphyrins, hexaphyrins, pentaphyrins, porphocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers

Abstract

The present invention relates to the field of conjugates comprising a first substrate which is attached to a least one photosensitizer and at least ont first quencher, and methods for their use. More particularly, the present invention relates to photodynamic therapy agents. The invention further relates to methods for decontaminating blood and methods for treating cancer or viral infection in a subject using the conjugates of the present invention.
PCT/US2004/038024 2003-11-14 2004-11-15 Activatable photodynamic therapy agents WO2005048944A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/383,487 US8133482B2 (en) 2003-11-14 2006-05-15 Activatable photodynamic therapy agents

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US51979403P 2003-11-14 2003-11-14
US60/519,794 2003-11-14
US55850104P 2004-04-01 2004-04-01
US60/558,501 2004-04-01

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/383,487 Continuation-In-Part US8133482B2 (en) 2003-11-14 2006-05-15 Activatable photodynamic therapy agents

Publications (2)

Publication Number Publication Date
WO2005048944A2 WO2005048944A2 (en) 2005-06-02
WO2005048944A3 true WO2005048944A3 (en) 2006-05-04

Family

ID=34623104

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/038024 WO2005048944A2 (en) 2003-11-14 2004-11-15 Activatable photodynamic therapy agents

Country Status (1)

Country Link
WO (1) WO2005048944A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9125829B2 (en) 2012-08-17 2015-09-08 Hallstar Innovations Corp. Method of photostabilizing UV absorbers, particularly dibenzyolmethane derivatives, e.g., Avobenzone, with cyano-containing fused tricyclic compounds
US9145383B2 (en) 2012-08-10 2015-09-29 Hallstar Innovations Corp. Compositions, apparatus, systems, and methods for resolving electronic excited states

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008039994A2 (en) * 2006-09-28 2008-04-03 The Trustees Of The University Of Pennsylvania Targeted photodynamic therapy agent
US9957546B2 (en) 2008-03-04 2018-05-01 The Trustees Of The University Of Pennsylvania Vivo detection of phospholipase activation
US9017974B2 (en) * 2011-06-06 2015-04-28 University Health Network Method for the synthesis of porphyrin-phospholipid conjugates
WO2014025370A1 (en) * 2012-08-10 2014-02-13 Hallstar Innovations Corp. Tricyclic energy quencher compounds for reducing singlet oxygen generation
WO2014139012A1 (en) 2013-03-15 2014-09-18 Suncor Energy Inc. Herbicidal compositions
WO2016157198A1 (en) * 2015-03-31 2016-10-06 Galia Blum Photodynamic quenched activity based probes and uses thereof in imaging and targeted therapy
CN105694851B (en) * 2016-03-08 2018-07-27 武汉大学 A kind of cancer target diagnosis and treatment fluorescence probe
WO2018175273A1 (en) * 2017-03-21 2018-09-27 The Regents Of The University Of Michigan Erg targeted therapy
US20230190933A1 (en) * 2020-05-12 2023-06-22 Institute Of Process Engineering, Chinese Academy Of Sciences Immunologically Active Peptide-Biliverdin Conjugate, Preparation Method Therefor and Application Thereof
CN116102741B (en) * 2023-04-10 2023-06-20 中国农业科学院农业质量标准与检测技术研究所 Magnetic nanocomposite for removing bee venom sensitizers, and preparation method and application thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6103751A (en) * 1998-06-22 2000-08-15 Health Research, Inc. Carotene analogs of porphyrins, chlorins and bacteriochlorins as therapeutic and diagnostic agents
US6159445A (en) * 1994-07-20 2000-12-12 Nycomed Imaging As Light imaging contrast agents
US6540981B2 (en) * 1997-12-04 2003-04-01 Amersham Health As Light imaging contrast agents

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6159445A (en) * 1994-07-20 2000-12-12 Nycomed Imaging As Light imaging contrast agents
US6540981B2 (en) * 1997-12-04 2003-04-01 Amersham Health As Light imaging contrast agents
US6103751A (en) * 1998-06-22 2000-08-15 Health Research, Inc. Carotene analogs of porphyrins, chlorins and bacteriochlorins as therapeutic and diagnostic agents

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MATAYOSHI E.D. ET AL: "Novel Fluorogenic Substrates for Assaying Retroviral Protease by Resonance Energy Transfer", SCIENCE, vol. 247, no. 4945, 23 February 1990 (1990-02-23), pages 954 - 958, XP002056345 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9145383B2 (en) 2012-08-10 2015-09-29 Hallstar Innovations Corp. Compositions, apparatus, systems, and methods for resolving electronic excited states
US9125829B2 (en) 2012-08-17 2015-09-08 Hallstar Innovations Corp. Method of photostabilizing UV absorbers, particularly dibenzyolmethane derivatives, e.g., Avobenzone, with cyano-containing fused tricyclic compounds

Also Published As

Publication number Publication date
WO2005048944A2 (en) 2005-06-02

Similar Documents

Publication Publication Date Title
WO2002096366A3 (en) Metallotetrapyrrolic photosensitizing agents for use in photodynamic therapy
WO2003043697A3 (en) Therapeutic light-emitting device
NO20023267L (en) Treatment of congestive heart failure in pretreated autologous blood
CR7330A (en) PROCEDURE FOR TREATING EYE NEOVASCULAR DISEASES
WO2004091531A3 (en) Methods and devices for epithelial protection during photodynamic therapy
WO2004062604A3 (en) Treatment of cancer with 2-deoxyglucose
DK1373215T3 (en) Gelanamycin derivatives suitable for the treatment of cancer
WO2005048944A3 (en) Activatable photodynamic therapy agents
AU2001297644A1 (en) B/b-like fragment targeting for the purposes of photodynamic therapy and medical imaging
WO2003032901A3 (en) Pathological tissue detection and treatment employing targeted benzoindole optical agents
WO2004064734A3 (en) Combination therapies for the treatment of cancer
CY1105818T1 (en) USES OF ET743 IN THE THERAPEUTIC TREATMENT OF CANCER
UY27186A1 (en) PHARMACEUTICAL FORMULATION
WO2001085213A3 (en) Supports for photosensitizer formulations
BRPI0517976A (en) treatment methods
IL158032A (en) Metal substituted non centrosymmetrical phthalocyanine analogues, their preparation and use in photodynamic therapy and in vivo diagnostics
WO2003032900A3 (en) Carbocyanine dyes for tandem, photodiagnostic and therapeutic applications
WO2008045378A3 (en) Treatment of infant hyperbilirubinemia using low dosages of stannsoporfin
BRPI0418157A (en) allogeneic tumor therapy
WO2000040229A3 (en) Synergistic tumorcidal response induced by histamine
WO2001024825A3 (en) Significance of dosimetry in photodynamic therapy of injured arteries
WO2003049804A3 (en) Treatment of genitourinary tract disorders
WO2003028629A3 (en) Chlorin photosensitizing agents for use in photodynamic therapy
AU2003210659A1 (en) Combination therapy for treatment of hiv infection
WO2001008704A3 (en) Dendrimer-photosensitizer complexes for medical applications

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase